Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, Nuclease Platform Development

Employer
Intellia Therapeutics
Location
Cambridge, MA, United States
Start date
Aug 25, 2020

View more

Discipline
Information Technology, Science/R&D, Biotechnology
Required Education
Masters Degree/MBA
Position Type
Full time
Hotbed
Genetown

Job Details

At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop potential cures. We bring new hope for people living with conditions including cancer, genetic disorders, viral infections, inflammatory disorders and many more.

Intellia is seeking an experienced Scientist to join our energetic, exciting and cross-functional team. The ideal candidate is high-energy, goal-driven and has extensive experience with different CRISPR-based gene editing technologies and will be responsible for helping drive emerging gene-editing technologies towards human therapeutics.

Responsibilities
    • Evaluate new technologies and approaches to support Intellia's Nuclease Platform Development
    • Design, execute and troubleshoot high throughput experiments to optimize gene editing efficiency in different mammalian immortal cell lines and primary cells via different delivery methods (Lentivirus, AAV, Lipid nanoparticles etc.)
    • Perform experiments using multiple instruments to measure mRNA and protein expression (RT-PCR, ELISA, MSD, Flow-cytometry etc.) and/or genome integrity (digital droplet PCR, Next-generation sequencing etc.)
    • Act as a liason and collaborate in a matrixed organization to optimize gene editing efficiency in different animal models
    • Document results in a timely manner in electronic notebooks and present data internally and with external collaborators.
    • Analyze and synthesize results to assess future directions


Qualifications
    • Masters in Biochemistry, Biophysics or Cellular and Molecular biology with 3- 5 years of research experience. Strong candidates with Bachelors in related disciplines with 5-7 years of experience will also be considered. OR PhD with relevant hands on experience.
    • Expertise with a broad spectrum of molecular biology, cell biology, and biochemical methodologies
    • Extensive experience in mammalian genome editing with CRISPR/Cas9-like technologies. Experience working with different tissue-types is a plus
    • Knowledge of the CRISPR landscape preferred
    • Experience with CAR or TCR-T cell therapies is a plus
    • Experience with structural biology of proteins and/or nucleic acids and/or automation is a plus
    • Experience with different protein engineering approaches is a plus


Skills
    • Ability to work effectively within a broader cross-functional team
    • Organized, self-starter with demonstrated problem-solving skills
    • Continuously seeks to improve existing scientific processes
    • Detail oriented, with strong verbal and written communication skills


#LI-DG1

What Intellia Stands For:

At Intellia, our mission is to develop potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threating diseases.

We push boundaries. We are focused on positively disrupting health care treatment of patients with genomic diseases. The values we live by and drivers we look for are:

- One is respect for individuals; our unique qualities and strengths; our own ways to understand, learn and improve. One is our single-minded determination to excel; to succeed together. One is you and us - trusting and counting on every single one of us.

- Explore because we seek new ways to tackle disease. Explore with unbounded minds...free from assumptions, open to ideas. Explore by staying curious, by pushing boundaries, overcoming obstacles. Explore means thinking of new ways.

- Disrupt by thinking courageously...and creating a better future. Disrupt by defying conformity; interrogating the status quo; questioning our momentum. Disrupt with challenging thoughts...with that breed of skepticism that shows you have better solutions.

- Deliver with your focus on the objective and your determination to complete the task. Deliver by advancing relentlessly and by maintaining high standards...even when nobody is watching. Deliver by staying accountable and pulling your weight. Deliver because patients are counting on us to make the promise reality. Get it done.

POSITION: Full-Time, Exempt

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Intellia's web-based application process is managed through Lever. Information submitted through application forms is collected by Lever and subject to Lever's privacy policy .

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert